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Abstract: The liver executes versatile functions and is the chief organ for metabolism of
toxicants/xenobiotics. Hepatocellular carcinoma (HCC) is the most common primary liver
malignancy and the third foremost cause of cancer death worldwide. Oxidative stress is a key factor
related with the development and progression of HCC. Nuclear factor erythroid 2 [NF-E2]-related
factor 2 (Nrf2) is a cytosolic transcription factor, which regulates redox homeostasis by activating the
expression of an array of antioxidant response element-dependent genes. Nrf2 displays conflicting
roles in normal, healthy liver and HCC; in the former, Nrf2 offers beneficial effects, whereas in the
latter it causes detrimental effects favouring the proliferation and survival of HCC. Sustained Nrf2
activation has been observed in HCC and facilitates its progression and aggressiveness. This review
summarizes the role and mechanism(s) of action of Nrf2 dysregulation in HCC and therapeutic
options that can be employed to modulate this transcription factor.
Keywords: hepatocellular carcinoma; Keap1-Nrf2-ARE pathway; microRNAs; Nrf2 dysregulation;
phytochemicals
1. Introduction
Hepatocellular carcinoma (HCC) is the one of the leading liver cancers in many countries and is
the fifth most common cancer worldwide [1]. Though liver cirrhosis contributes to 80–90% of HCC
development, other factors, viz aflatoxin B1, diabetes, dietary habits, excessive alcohol intake, infection
with Hepatitis-B-virus (HBV) and Hepatitis-C-virus (HCV), iron accumulation, non-alcoholic fatty liver
disease and tobacco use also result in HCC development [2]. Many of these factors modulate the redox
homeostasis in the liver, eventually causing hepatocarcinogenesis [3]. The disparity in the production
of undue reactive oxygen species (ROS) and their disposal ends in oxidative stress. The Kelch-like
ECH-associated protein 1 (Keap1)-nuclear factor E2-related factor 2 (Nrf2)-antioxidant response
elements (ARE) pathway protects the cell against oxidative stress [4]. Nrf2, a CNC-bZIP transcription
factor, regulates a prodigious number of genes, that can regulate redox status, detoxification of toxicants
and transport of drugs. Thus targeted modulation of Nrf2 can be employed to treat various chronic
diseases including cancer. On the contrary, the sustained enhancement of Nrf2 may also promote the
survival and progression of cancer [5]. This review briefly summarizes the molecular structure, role
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and potential regulation of Nrf2 and also elaborates upon potential pharmacological strategies that
can be used to target this transcription factor in cancer.
2. Epidemiology of HCC
The occurrence of HCC differs based on geographical regions [6,7] (Figure 1). HCC causes high
impermanence and poor long term survival leading to a consequential worldwide health implications.
According to the report in cancer facts and figures, the 5-year relative survival rate is 18% for liver cancer
patients diagnosed with all stages. The 5-year survival rate increases to 31% when 43% of patients are
diagnosed with a localized stage of disease [8]. Hepatitis-B-virus (HBV) and Hepatitis-C-virus (HCV)
infections are the most primary risk factors for HCC development. HBV and HCV infections lead to
HCC development, with an incidence of around 80% in Africa/East Asia and 20% in Western Europe
and North America. Globally more than 400 million people are persistently infected with HBV and
around 804/100,000 men and 178/100,000 women are HBV positive [9]. 170 million people worldwide
are chronically infected with HCV and around 80% of HCC patients in low and intermediate income
countries are HCV positive.
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The various causative factors underlying HCC development include alcohol drinking, aflatoxin
exposure, tobacco smoking, obesity, diabetes and genetic factors [10]. Fungal species produce
carcinogenic aflatoxin that contaminate food, which then induces liver damage [11]. Sub-Saharan
Africa, Southeast Asia and China are the most affected regions of aflatoxin contamination [12]. Similarly,
chronic alcohol intake is a main risk factor for HCC development, with an incidence rate of 0.01/100
people with irrh sis. Less th n 40 g/day of alcohol i consid red as a moder te alcohol intake and
40–60 g/d y is onsidered as heavy alcohol dri king. Alc hol drinkers who are HBV and HCV positive
have a higher risk f developing HCC compared with non-drinkers [13].
In Western societies, infl mmation with non-alcoholic fatty liver disease leads to the development
of HCC, along with obesity nd type 2 diabetes mellitus [14,15]. Among 30–40% of patients with
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obesity-related metabolic changes are at risk of developing HCC worldwide [13]. Type 2 diabetes
mellitus patients with cirrhosis, HCV infection, chronic liver disease and HBV infection generally
exhibit a relatively higher risk of HCC [16]. Tobacco smokers may also have a 1.5 time’s higher risk of
developing HCC than non-smokers [17].
3. Molecular Pathogenesis of HCC
Hepatocarcinogenesis is a multistep process, which involves alterations in gene expression pattern
associated with mutations in liver-specific genes. These genes are associated with cell proliferation,
cell cycle progression, apoptosis and metastasis, which include p53, adenomatous polyposis coli (APC),
breast cancer 1 (BRCA1), breast cancer 2 (BRCA2), Rb, Ras and β-catenin [18]. Activation of growth
factor regulating signalling pathways (insulin- like growth factor (IGF), epidermal growth factor (EGF),
hepatocyte growth factor (HGF)), cell differentiation related pathways (Wnt, Hedgehog, Notch) and
angiogenesis-induced signalling pathways (vascular endothelial growth factor) also promotes HCC
pathogenesis [19].
Additionally, mutations and epigenetic alterations can also contribute to carcinogenesis.
Specifically, 30–60% of HCCs are reported to exhibit mutations in the telomerase RNA component
(TERC) and the telomerase reverse transcriptase (TERT) [20]. Consequently, down regulation of
p53 or p53 mutation activates aggressive oncogenic pathways as well as development of HCC [21].
Accumulation of specific mutations in codon 249 of the seventh exon in p53 inhibits cellular apoptosis
and induces the proliferation of tumour cells. Deregulation of p14/ARF, growth arrest and DNA
damage inducible protein (GADD45) are related with a high level of chromosomal instability with
epigenetic alterations [22]. Special cases of HCC are mainly caused by site-specific hypomethylation
and site-specific hypermethylation. In HCC, DNA methylation in specific gene regions results in
genetic instability and silencing of tumour suppressor genes. HBV and HCV primarily target the DNA
methyltransferases (DNMTs), GSTP1, E-Cadherin promoters and Ras/Raf/ERK signalling pathway
genes [23,24].
Similarly, signalling pathway deregulation has also been attributed to HCC development.
Mainly, Wnt/β-catenin, Ras, p14ARF/P53, p16INK4A/Rb, transforming growth factor-β (TGF-β)
and PTEN/Akt signalling pathway deregulation is commonly associated with the development of
HCC [25]. The Wnt/β-catenin signalling pathway is involved with cellular proliferation, development
and motility and an overactivated Wnt/β-catenin pathway is involved in the development of
human cancer [26]. Hyperactivation of the Ras/mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinae (PI3K)-Akt kinase signalling pathways has been observed in 50% of
HCC [27]. Currently, TGFβ appears to play a significant role in cellular growth suppression in
the initial stages as well as invasiveness in the final stages of HCC development [28]. However,
HCC arises with the JAK/STAT pathway activation through inactivation of suppressors of cytokine
signalling (SOCS) and signal transducers and activators of transcription (STAT)-induced STAT inhibitor
1(SSI-1) [29].
Recent research revealed that Nrf2 target genes can also play a potential role in hepatic
injury, inflammation and hepatocarcinogenesis. HCV-induced hepatocarcinogenesis can involve the
phosphorylation and nuclear translocation of Nrf2 by MAPK, casein kinase 2 and PI3K, which regulate
the Nrf2-ARE genes by causing up regulation of Maf proteins [30]. However, HBV infected cells
can also elicit up regulation of the Nrf2-regulated proteasomal subunit PSMB5 and cause a down
regulation of immunoproteasome subunit PSMB5i [31]. Consistent with this, HepG2 cells expressing
CYP2E1 showed an up-regulation of Nrf2 mRNA as well as protein expression and modulates the
expression of various downstream genes (GCLC and HO-1) [32].
4. Oxidative Stress and Inflammation in HCC
Oxidative stress can be one of the major causes underlying HCC development, by driving
DNA damage, reactive oxygen species (ROS), reactive nitrogen species (RNS) production and
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altered protein expression. Oxidative stress can cause mitochondrial damage to reduce the electron
transport chain and is associated with an elevated level of ROS, tumour necrosis factor alpha (TNF-α)
production, mitochondrial respiratory chain damage and cytochrome c oxidase impairment [33].
Specific causes of oxidative stress in the liver trigger chronic inflammation in hepatic stellate cells
(HSCs), dendritic cells (DCs), Kupffer cells (KCs) and liver sinusoidal endothelial cells, with the
suppression of cytokine production (Interleukin-(IL)-6) and cellular apoptosis [34]. These hepatic
inflammation-induced superoxide anions are transformed by superoxide dismutase to produce high
levels of H2O2 in hepatocytes.
Toxic compound/carcinogenic agent exposure causes oxidative stress in hepatocytes and
augments the translocation of Nrf2 into the nucleus. The Nrf2 expression is up regulated under
the oxidative stress condition and thus regulates proliferation, survival and invasion processes in
the tumour cells [35]. Zhang et al. [36] reported that Nrf2 promoted the proliferation and metastasis
of HCC through the diminution of the apoptotic signalling pathway (Figure 2). HCV infections can
negatively regulate the expression of Nrf2-ARE regulated genes to induce oxidative stress markers,
leading to the viral hepatitis. Moreover, HCV-induced hepatotoxicity increased the accumulation of
Nrf2 in a time-dependent manner, resulting in the transcriptional activation of Nrf2-ARE related genes
associated with PI3K, casein kinase 2 and MAPKs expression [37].
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t characteristic domains: BT , IVR and DGR domains. In the u str ssed condition, Keap1 promotes
Nrf2 degradation so th t the level of Nrf2 remains very low. During oxidative stress, Nrf2 gets activated
to maintain red x homeostasis. In HCC, sustained Nrf2 activation leads to cellular proliferation and
resistance agai st drugs.
Specific ROS may be generated by the direct effect of the β-oxidation pathway, leading to the
leakage of electrons in the mitochondrial electron transport chain [38]. Recently, HSCs and KCs
had a higher response to oxidative stress, which can directly lead to nuclear factor kappa B (NF-κB)
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activation that resulted in NO, ROS, cytokine synthesis and necrosis [39]. Increased ROS can induce
more mitochondrial membrane permeability and DNA damage that has been found to be associated
with deletion and mutation of apoptosis-specific genes in HCC [40]. HBV/HCV infection-induced
oxidative stress causes specific gene mutations in the diverse processes of cell cycle, DNA repair and
apoptosis [41]. Chronic integration of HBV into the genetic material may also result in accumulation of
cancer-specific gene mutations. HBV infection can cause an increased release of IL-1β, IL-6, CXCL8 and
TNF-α via NF-κB involvement [42]. The HBV multifunctional protein (called HBx) accumulates into the
hepatocyte mitochondria to generate ROS, which results in the activation of the MLK3/MKK7/JNKs
signalling pathways [43,44]. Similarly, HCV antigen deposition is associated with disruption of the
immune system, with the resultant production of hydroxyl radicals, toxic ROS, perforin, granzyme B,
inflammation and fibrosis [45]. Oxidative stress through HCV infection results in hepatocyte DNA
mutation, infinite regeneration cycles and hepatocyte apoptosis [46]. Sequence variations in patatin
like phospholipase domain containing 3 (PNPLA3) might lead to hepatic steatosis and liver injury.
The polymorphism in PNPLA3 has been also reported to be associated with HCC [47].
The circulating cell-free DNA (cfDNA) are 160–180 base pair fragments, with the major contributor
of this cfDNA being white blood cells. Circulating cell-free tumour DNA is released into the blood
stream from the tumour cells undergoing apoptosis and necrosis. This circulating DNA could serve
as a biomarker for the detection of metastasis [48]. Better clinical management of HCC can be made
possible through determining the quantity and methylation status of cfDNA. The role and potential
use of cfDNA in the diagnosis, management and screening of HCC has been reviewed in detail [49].
Similarly, microRNA (miR) can cause an inflammatory process and oncogenesis [50]. Oxidative stress
is one of the important events that effectively down regulates the miRs (miR-92, miR-199a, miR-199b
and miR-122a) in the immune system and directly causes HCC [51].
5. Structure of Nrf2
The NFE2L2 gene encodes a cap “n” collar (CNC) basic-region leucine zipper (bZIP) transcription
factor, Nrf2 [52,53]. Nrf2 (66-kDa) consists of 7 Nrf2-erythroid cell-derived proteins with CNC
homology (ECH) domains with 605 amino acids (Neh 1–7); each of the Neh domains executes distinct
functions. The Neh1 domain is essential for two functions: One being DNA binding by the CNC-bZIP
region and the other is dimerization with other transcription factors [54] (Figure 3). The amino acid
residues of the Neh1 domain are basic and hence facilitate the binding with acidic DNA. This Neh1
domain is conserved across different species and thus distinguishes itself as an important functional
domain within Nrf2. In addition, Nrf2 stability is mediated by the Neh1 domain on interaction with
a conserved metazoan E2 ubiquitin conjugating-enzyme (UbcM2) [55]. When disengaged from the
Keap1 protein complex, the bipartite nuclear localization signal in the Neh1 domain gets uncovered so
that the translocation of Nrf2 happens.
The major regulatory N-terminal Neh2 domain interacts with Keap1 through two highly
conserved motifs: ETGE and DLG [56,57]. Both these motifs bind the Kelch domain of Keap1.
The ubiquitination of 7 lysine residues in this Neh2 domain directs Nrf2 for proteasomal degradation,
thus Neh2 is mandatory for negative regulation.
The transcriptional activation of Nrf2 regulated genes is executed by Neh3, Neh4 and Neh5
domains along with their coactivators [58]. The Chromo-ATPase/helicase DNA-binding protein family
member, CHD6, facilitates the activation of transcription by binding with the Neh3 domain [59].
Similarly, a CH3 domain of coactivator cyclic adenosine monophosphate (cAMP)-responsive
element-binding (CREB) protein triggers Nrf2 transactivation through interaction with both the
Neh4 and Neh5 domains [58]. Both these Neh4 and Neh5 transactivation domains elevate the
Nrf2-targeted ARE genes’ expression in association with nuclear cofactor receptor-associated
coactivator 3 (RAC3)/AIB-1/steroid receptor coactivator-3 (RAC3/AIB1/SRC-3) [60]. The cellular
localization of Nrf2 is regulated by the Neh5 domain, which possesses a redox-sensitive nuclear
export signal.
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The Neh6 domain carries two important motifs: DSGIS and DSAPGS, which are highly conserved
and the β-transducing repeat-containing protein (β-TrCP) recognizes these two motifs [61]. Glycogen
synthase kinase-3β (GSK3β) phosphorylates the DSGIS motif, which makes binding of β-TrCP to Neh6
more efficient. GSK3β directs the proteasomal degradation of Nrf2 independent of Keap1, with the
recruitment of the Skp1-Cul1-F-box (SCF) protein ubiquitin ligase complex [62–64]. As the degradation
is independent of Keap1, the Neh6 domain has been designated as the redox-insensitive region of
Nrf2 [65].
The retinoid X receptor alpha (RxRα)-an Nrf2 repressor-associates with the Neh7 domain to
inhibit the transcriptional activity of Nrf2 [66].
6. Structure of Keap1
Once scientists had strong evidence that a cellular factor can negatively regulates Nrf2, the quest
for identification of the negative regulator began. Nrf2 repression was controlled by a single conserved
domain-Neh2-in Nrf2. The location of this specific Neh2 domain led to the discovery of Keap1-a new
negative regulator [56]. Keap1 binds this N-terminal Neh2 domain and represses Nrf2. It was named
Keap1 due to its similarity with Drosophila Kelch-a cytoskeleton binding protein.
Keap1 is a Kelch-like (KLHL) protein, which belongs to the family of BTB-Kelch proteins. Keap1
complexes with Rbx1 and Cullin 3 (Cul3) and forms multicomplex Cullin-really interesting new gene
(RING) ligases (CRLs) for polyubiquitination and subsequent degradation of Nrf2; thereby preventing
Nrf2 translocation into the nucleus and binding of Nrf2 with antioxidant response elements (AREs) in
the DNA. Similar to KLHL protein, Keap1 has three main domains with an N-terminal region (residues
1–49), a Broad complex, Tram-track, a Bric a brac (BTB) domain (residues 50–179), an intervening
region (IVR) with residues 180–314, the double-glycine repeat or Kelch domains and carboxy terminal
region (CTR) (residues 327–611) [67,68]. Being a substrate adaptor, with its BTB domain, Cul3 and
Nrf2 are linked, the IVR domain binds Cul3 and the Kelch domain binds motifs in the Neh2 domain of
Nrf2 (Figure 3).
The BTB domain (aka POZ domain) is responsible for the both homo- and heterodimerization [69].
The N-terminal BTB domain is essential for dimerization. It docks the Cul3-dependent E3 ubiquitin
ligase complex [70,71]. The IVR domain (aka BACK domain) mediates the interaction of Cul3
with Keap1 through the 3-box bihelical motif in the proximal part in the N-terminal end called
the ‘3-box’ [72]. The IVR cysteine residues act as sensors of electrophiles and ROS and thus play an
essential role in redox homeostasis. The IVR domain connects the BTB and the Kelch domain.
The Kelch domain (aka DGR or DC domain) consists of 6 Kelch repeats forming 6 β-propeller
blades (I-VI). Each blade possesses 4-antiparallel β-sheets (beta strands A–D) [73]. Loops of different
lengths link these 4 β-strands as the loops arise from the β-propeller central core. The bottom of the
β-propeller has long loops linking β-strands B to C and D to A, while the top of the β-propeller has
short loops joining β-strand A to B and C to D. The central portion of the propeller forms a channel
that runs through the entire domain. The conserved amino acid residues in the Kelch domain include a
tyrosine (βC), a tryptophan (βD) and a double-glycine repeat (DGR) and hence are named the DC and
DGR domain [74]. The Keap1 DGR domain is vital for the interaction with the Neh2 domain of Nrf2,
whereas the tyrosine and tryptophan are needed for the hydrophobic packing between blades [73].
The Kelch domain holds Keap1 in the cytoplasm via interaction with the actin cytoskeleton [75].
The Keap1 binds the N-terminal Neh2 domain of Nrf2 with the Kelch domain [76]. The Kelch domain
of two Keap1 units binds to the Neh2 ETGE motif with high affinity and DLG motifs with low affinity
separately [77]. The Kelch domain of one Keap1 sequesters the Nrf2 in the cytoplasm with the ETGE
motif, whereas the DLG motif of the other Keap1 locks Nrf2. In an unstressed state, two Kelch domains
sequester Nrf2 on binding with the Glu-Thr-Gly-Glu (ETGE) and Asp-Leu-Gly (DLG) motifs on the
Neh2 domain [78].
The disruption of Keap1 can also lead to elevated cellular Nrf2 activity. This disruption happens
when somatic mutations occur in Keap1 [79,80], Keap1 translational repression or mRNA degradation
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by miRs [81,82] and hypermethylation of cytosine in the Keap1 promoter [83]. All these occur in human
cancer and hence Keap1 may act as tumour suppressor. Moreover, as a result of Keap1 disruption,
constitutive Nrf2 activation can lead to drug and radiation resistance in tumours [84].
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7. Keap1-Nrf2-ARE Pathway
Nrf2 is the primary governor of the antioxidant response pathway [85]. During normal
physiological conditions, Keap1 acts as a negative regulator of Nrf2 and maintains a basal level
of Nrf2 in the cytoplasm by degradation through the ubiquitin-proteasomal system. In contrast, the
level of Nrf2 has been reported to be elevated during the stress conditions, primarily during oxidative
stress. The Keap1 IVR domain cysteine residues act as redox sensor and when they get oxidized,
the Nrf2 is disengaged from the regulatory complex [86]. Then, Nrf2 becomes phosphorylated and
translocates into the nucleus as the nuclear localization signal sequences are exposed. Within the
nucleus, the prime dimerizing partners-small v-maf musculoaponeurotic fibrosarcoma oncogene
homolog (sMaf) proteins-accompany Nrf2. The Nrf2-sMaf heterodimers bind specific AREs within the
DNA, which results in the recruitment of other transcriptional activators and triggers the transcription
of Nrf2 target genes [87,88]. In HCC, this pathway may be enhanced and promotes cellular proliferation
and progression. Thus, Nrf2 has been considered both as a tumour suppressor and an oncogene [89].
As it protects the cell from stress insults, Nrf2 is considered to be a tumour suppressor [90]. But during
the initiation of cancer, oxidative stress persists, leading to the hyperactivation of Nrf2, which can then
promote the survival of cancer cells [91]. During the course of its action in cancer cells, Nrf2 may also
confer cellular resistance against chemotherapeutics and radiation therapy.
Cancers 2018, 10, 481 8 of 29
8. Nrf2 and Keap1 Mutations Lead to HCC
ROS generated by either endogenous metabolites or exogenous toxicants cause mutations in
key genes to initiate cancer. Aberrant Nrf2 activation occurs due to somatic mutations in Keap1 and
Nrf2, which can lead to the disrupted binding between Keap1 and Nrf2. Driver mutations offer
a selective growth advantage and can promote cancer. Recently a study identified 30 candidate
driver genes from 503 liver cancer genome data [92]. Most of these genes encode activators of the
mammalian target of rapamycin (mTOR) pathway, chromatin remodellers and metabolic enzymes.
Yet another study identified point mutations, structural variations and integrations of viral DNA in
coding and non-coding regions in 300 liver cancers from Japanese individuals [93]. The frequency of
mutations in Nrf2 (5.1%) is greater than Keap1 (3.2%) in HCC [94]. The mutations in Keap1 and Nrf2
occur as late events in HCC, as observed in the advanced stage of human liver carcinogenesis [95].
In contrast, the mutations in Nrf2 occur as an early event in the resistant hepatocyte model, leading to
carcinogenesis [96]. In the case of Nrf2, most of the mutations fall in the low affinity DLG and high
affinity ETGE motifs of the Neh2 domain in HCC [96,97]. Yet, mutations in the DLG motif can induce
the activation of Nrf2. The loss-of-function Keap1 mutations induce persistent activation of Nrf2.
Next generation sequencing data indicated that 6% of HCC are caused by mutations/ROS induced
oxidative stress conditions. Dissociation of Keap1 and Nrf2 by oxidative stress increases the nuclear
translocation of Nrf2, which thereby regulates the expression of antioxidant genes and [98].
It has been reported that 78.6% of Nrf2/Keap1 mutations occur in early HCC, 59.3% mutations in
advanced HCC and 71% in early pre-neoplastic lesions. The mutation of Keap1 has a lower frequency
compared to Nrf2 in HCC and preneoplastic lesions [93]. Nault and Zucman-Rossi [99] reported
that 8% of mutations were identified in Keap1 and the NFE2L2-Keap1 pathway and were associated
with high transcript levels. Specifically, the Nrf2 DLG motif contains 80% of its mutations in codons
encoding amino acid residue 29 and 100% of its mutations in amino acid residue 32 [100]. A recent
study reported that Nrf2 mutations were increased in the specific motif LxxQDxDLG (spanning amino
acid 17–32) or DxETGE (amino acid 77–82) that binds the Kelch domain in Keap1. These mutations
easily up regulate the Nrf2 target genes in proneoplastic lesions [96].
9. Nrf2 in HCC
Hepatocytes that are exposed to chemical carcinogens can accumulate ROS, leading to cellular
oxidative stress and resulting in hepatocyte transformation of HCC progenitor cells [101]. The transient
activation of Nrf2 offers protection during this process but in contrast, persistent activation of Nrf2 can
drive the oncogenic process. The use of antioxidants as Nrf2 activators will lead to the sustainable
activation of Nrf2, thereby contributing to carcinogenesis. Hence, a promising therapeutic strategy is
the use of Nrf2 inhibitors, which might deter the progression of chronic liver damage to HCC.
In HCC, Nrf2 expression has been found to be related with survival of the cells and
clinicopathological factors [36]. The increased expression of Nrf2 was corroborated with differentiation,
metastasis and size of the tumour in HCC. In addition to Nrf2 expression, the proliferation and invasion
of HCC cells were evidenced by the expression of Bcl-xL and matrixmetallaproteinase-9. Hence,
Nrf2 expression could be utilized as an independent prognostic factor in HCC. An interesting
observation was made in Hepa-1 and HepG2 cells where Nrf2 mediated the expression of Bcl-xL
with AREs in the promoter region of Bcl-xL [102]. This Bcl-xL expression induced by Nrf2
prevented apoptosis and promoted drug resistance as well as survival in both the cell lines. In HCC
patients, increased Nrf2 expression and 8-hydroxyguanosine (8-OHdG) lesions were observed [103].
This elevated 8-OHdG was found to be associated with poor survival. Similar observations were also
made in HepG2 cells on exposure to H2O2.
In Nrf2-deficient mice, chronic exposure to non-genotoxic hepatocarcinogens-pentachlorophenol
(PCP) and piperonyl butoxide (PBO)-triggered oxidative stress [104]. This oxidative stress
can stimulate the proliferation and progression of preneoplastic lesions to neoplasms. This is
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indicative of Nrf2 dysregulation increasing the risk of carcinogenesis elicited by non-genotoxic
environmental carcinogens.
The presence of high affinity enhancer element (GPE1) in the placental glutathione S-transferase
(GST-P) regulates the expression of GST-P through Nrf2-MafK [105]. The Nrf2-MafK heterodimer
can also drive the expression of GST-P in early hepatocarcinogenesis and in HCC but not in normal
liver cells.
10. Autophagy, p62 and Nrf2 in HCC
An interesting observation was made in Japanese HCC, where phosphorylation of p62 (aka
sequestome-1) conferred Nrf2 activation in contrast to non-tumour regions [106]. The phosphorylation
of p62 and its contribution to tumorigenesis has to be further investigated. Yet, another study has
reported that p62 expression contributed to the resistance of HCC against ferroptosis [107], which is a
form of regulated cell death induced by lipid ROS generated by iron-species [108]. Erastin, sorafenib
and buthionine sulfoximine can induce ferroptosis in HCC. p62 activation brings in resistance against
these compounds in HCC. p62 activated Nrf2 by degrading Keap1, which eventually triggered the
transcription of Nrf2-target genes-Nqo1, HO-1 and FTH1. These Nrf2-target genes reduce the lipid
peroxidation and regulate iron homeostasis in HCC, thereby conferring resistance against ferroptosis.
This p62-Keap1-Nrf2 pathway activation can mediate resistance of HCC against ferroptosis inducing
compounds. Hence, Nrf2 inhibitors in combination with ferroptosis inducers may serve as a promising
therapeutic strategy for liver cancer.
Relentless Nrf2 activation with the accumulation of p62 was identified in autophagy-deficient mice
and in human HCCs [109]. The homeostatic level of p62 is the key in the pathogenesis of liver injury,
where autophagy regulates the p62 levels [110]. The cytoplasmic inclusion body formation is under the
control of p62 levels. The deficient autophagy leads to liver injury through intracellular inclusion body
formation. The selective autophagy substrate p62 can accumulate during the suppression of autophagy
and activate Nrf2 [111]. This increased p62 leads to the competition of p62 with the binding of Nrf2
with Keap1. The p62-Keap1 complex aggregates in turn can stabilize Nrf2 and the activated Nrf2
binds AREs and triggers the transcription of Nrf2 target genes. During oxidative stress, p62’s affinity
with Keap1 increases the phosphorylation of p62 and eventually competes with Nrf2’s binding with
Keap1. This suppression of Keap1 augments the activation and translocation of Nrf2 into the nucleus,
where Nrf2 activates genes to reprogram redox homeostasis and thus promotes the proliferation of
HCC. This activation of p62 occurs when the autophagic process is deregulated in HCC cells (Figure 4).
An interesting observation was made that p62 is essential for the induction of HCC in mice during
preneoplasia [112]. This elevated expression of p62 enables the HCC-initiating cells to survive from
stress and also protects them from oxidative damage induced cell death.
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The domains of p62 and their interacting partners. (B) Under normal physiology, Nrf2 is held by
Keap1 and directs Nrf2 for proteasomal degradation. During deregulated autophagy, augmentation
of p62 occurs through phosphorylation of p62. Upon phosphorylation, p62 sequesters Keap1 and
disengages Nrf2 from Keap1, leading to the activation of the Keap1-Nrf2-ARE pathway, which results
in antioxidant defence, survival and metabolic reprogramming in HCC.
An impediment in autophagy induces post-translational modifications in p62 such as mTOR
phosphorylation of S349 in the STGE motif (KIR domain) of p62, PKA phosphorylation of S24 of
the PB1 domain of p62 and unc-51-like kinase 1 (ULK1), TANK-binding kinase 1 (TBK1) and casein
kinase 2 (CK2) phosphorylation of S403 in the UBA domain of p62 [113]. All these phosphorylation
events in p62 augment p62-Keap1 binding, ultimately resulting in the activation of Nrf2. Though these
phosphorylation events are reported in different studies, the mode of activation of p62 in HCC was
not studied in detail. Such future investigations will shed light on new therapeutic targets in HCC.
The role of the Nrf2-p62 pathway in HCC has previously been reviewed in detail [114].
Similarly, increased phosphorylation of p62 advanced malignancy in HCV positive HCC
patients [115]. Through Nrf2 activation, phosphorylation at S349 in p62 enhanced the synthesis
of glutathione and UDP-glucuro ate from glucose thr ugh the glucuronate pathway. HCV positive
HCC patients r vided evidence that p62 activation of Nrf2 reg l tes metabol c pathways, eventually
promoting malignancy. Besides accelerating cellular proliferation, GSH brings in tolerance against
chemotherapeutics by exporting th m into the extracellular space through multidrug resistance (MDR)
proteins. Th de elopment of MDR in HCC through the activation of Nrf2 has been reviewed
elsewhere [116]. Metabolic reprogramming is the key event elicited by the p62-Keap1-Nrf2 pathway in
HCC. Therefore, drugs that target phosphorylated p62 could be a therapeutic agent in HCC. K67 was
identified in a chemical screen to disrupt the interaction between phosphorylated p62 and Keap1,
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which reinstated E3-ligase adaptors and eventually directing ubiquitination and degradation of Nrf2
by Keap1 in HCC cells [115]. Thus, K67 inhibited cellular proliferation and promoted susceptibility to
anti-cancer drugs in HCC.
11. Phytochemicals/Molecules Can Elicit Activation of Nrf2 in HCC
Phytochemicals and other molecules display the potential to elicit Nrf2 activation in HCC
directly or through other signalling mechanisms (Figure 5). Gankyrin (gann ankyrin-repeat protein)
is the p28 component of the 26S proteasome and this seven ankyrin-repeat protein is evidenced
as an oncoprotein [117]. The increased expression of gankyrin was shown to be higher in HCCs
than in non-cancerous hepatic tissues [118,119]. Oxidative stress is the prime factor that leads
to hepatocarcinogenesis [3]. Gankyrin has been observed to protect the HCC cell from oxidative
stress [120]. The positive feedback loop between Nrf2 and gankyrin was established in human HCC
to sustain redox homeostasis. Under oxidative stress, gankyrin expression abrogates ROS through
the activation and stabilization of Nrf2 [120]. Gankyrin competes with Nrf2 and binds with the Kelch
domain of Keap1, eventually preventing the ubiquitination and degradation of Nrf2. Interestingly,
the promoter of gankyrin carried AREs and as a result, Nrf2 activation not only maintained homeostasis
but also triggered the expression of gankyrin through a feedback loop [120]. Thus, gankyrin connects
the link between oxidative stress and HCC development. The disruption of the interaction between
gankyrin and Keap1 may serve as an effective therapeutic strategy against HCC.
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During the knock down of Nrf2, AICAR fails to regulate redox homeostasis in HCC. While the AMPK
is silenced, the Nrf2 still gets activated on treatment with AICAR in HCC. This activation of the Nrf2
pathway irrespective of AMPK activity revealed that AICAR and its metabolite ZMP triggers Nrf2
activation via a non-canonical pathway. The mechanism of activation of Nrf2 by AICAR requires
further investigation to identify new players.
Prostaglandin reductase 1 (PTGR1), aka NADP+ -dependent leukotriene B4
12-hydroxydehydrogenase, is essential for prostaglandin and eicosanoid catabolism and responds
to inflammation and antioxidants [123]. In both a human clinical and a diethylnitrosamine (DENA)
induced hepatocarcinogenesis rat model, the expression of PTGR1 was elevated [124]. The increased
expression of Ptgr1 in hepatocarcinogenesis increased cellular proliferation with reduced time and
prevented the apoptosis elicited through oxidative stress [125]. An interesting observation is that Nrf2
regulated the expression of Ptgr1, which carried an ARE upstream (−653) of the transcription start site.
In addition to Ptgr1, the expression of other Nrf2 target genes Gclc, Nqo1 and Gstp1 was also elevated
to curb the oxidative stress. Thus, stable expression of PTGR1 may reduce the proliferation time,
enable apoptosis evasion and offer metabolic adaptation.
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is a homovanilic acid derivative found in
red chilli pepper and has chemoprotective effects [126]. Capsaicin treated HepG2 cells generated ROS,
which on interaction with Nqo1 inhibited its enzyme activity. The resulting increased ROS activated
the PI3K-Akt signalling pathway through the phosphorylation of Akt, leading to the activation of
Nrf2 [127]. Nrf2 then increased the expression of HO-1 while capsaicin inhibited Nqo1 activity, leading
to the increased generation of ROS in HepG2 cells.
Crotonaldehyde is a highly reactive α, β-unsaturated aldehyde and a main constituent of cigarette
smoke and is also present in bread, cheese, fruits, milk, meat and vegetables [128]. In HepG2
cells, crotonaldehyde induced HO-1 expression through the activation and translocation of Nrf2
into the nucleus [129]. Crotonaldehyde triggered activation of the protein kinase C-δ and p38
mitogen-activated protein kinase pathway, which ultimately activated the Nrf2 pathway. HO-1 is the
primary player in the crotonaldehyde activated HepG2 cell survival pathway to counteract apoptosis
and could serve as therapeutic target in crotonaldehyde promoted tumour resistance. Another plant
product, tigloylgomisin H (TGH), is a lignan from the fruit of Schisandra chinensis and displays the
potential to activate and translocate Nrf2 into the nucleus [130]. TGH induced NQO1-a phase II
detoxification enzyme-in Hepa1c1c7 and BPrc1 cell lines. Hence TGH could serve as a potential HCC
preventive agent.
Rebaudioside (13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-gluco pyra nosyl)
oxy]kaur-16-en-18-oic acid β-D-glucopyranosyl ester) is a steviol diterpene glycosidic constituent
from the Stevia rebaudiana Bertoni leaves [131]. Rebaudioside (Reb A) is a natural sweetener with 250 to
450 times more sweetness than sucrose and is used as a non-caloric sweetener in many countries [132].
Several pharmacological and toxicological properties of Reb A were reviewed recently [133]. Reb A
displayed antioxidant activity in HepG2 cells [134], where it alleviated the oxidative injury induced by
carbon tetrachloride (CCl4). Nrf2 activation elicited by Reb A was evidenced in CCl4-treated HepG2
cells. Oxidative damage was recuperated by HO-1 and NQO1 expression, followed by the activation of
Nrf2. This enhancement of Nrf2 activation occurred through the upregulation of JNK, ERK, MAPK and
PKCε signalling.
Citrinin [(3R,4S)-8-hydroxy-3,4,5-trimethyl-6-oxo-4,6-dihydro-3H-isochromene-7-carboxylic acid]
is a mycotoxin and a contaminant in human foods. Citrinin is produced by fungal strains from the
genera Aspergillus, Monascus and Penicillium [135]. Citrinin inhibited the proliferation of HepG2 cells
through the generation of ROS, leakage of lactic dehydrogenase and depolarization of mitochondrial
membrane potential and elicited apoptotic cell death due to DNA damage [136]. Pelargonidin is
a natural polyphenolic anthocyanidin pigment found abundantly in berries and radishes [137].
Pre-treatment with pelargonidin chloride (PC) reduced the cytotoxicity induced by citrinin in HepG2
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cells. Mechanistic insights revealed that PC enhanced the level and activity of detoxification enzymes
through activation of the Keap1-Nrf2 pathway.
The pomegranate fruit from Punica granatum is called superfruit for its enormous amount
of polyphenolic constituents and virile antioxidant properties [138]. Pomegranate juice offered
protection against systemic oxidative stress in mice [139]. The pomegranate emulsion (PE) prevents rat
hepatocarcinogenesis induced by DENA, which emulates human HCC [140]. The active constituents
in the PE induced the transcriptional activation of hepatic antioxidant and carcinogen detoxifying
enzymes in DENA treated animals through the activation of Nrf2. Oxidation of proteins and lipids gets
attenuated with PE. Thus, active constituents present in the PE could act as cancer preventive agents.
Phytochemicals such as phenethyl isothiocyanate, indole-3-carbinol, protocatechuic acid and
tannic acid increased the expression of phase II enzymes (GSTA, GSTP, GSTM, GSTT and NQO1) and
antioxidant enzymes (CAT, SOD, GR and GPx) in HepG2 cells [141]. This phase II and antioxidant gene
expression was increased through activation of the Keap1-Nrf2-ARE signalling pathway. The induction
was far more effective with phenethyl isothiocyanate and indole-3-carbinol than protocatechuic acid
and tannic acid.
Camptotheca acuminata produces a planar pentacyclic quinolone alkaloid called camptothecin,
which possesses anti-tumour activities [142]. Camptothecin is a DNA topoisomerase I poison that
complexes with type I DNA topoisomerase and stabilizes the complex, preventing the cleavage and
relegation reactions during DNA replication that ultimately halt cellular proliferation. In recent
years, camptothecin was identified as a potent Nrf2 inhibitor. In HCC cells (HepG2 and SMMC-7221)
and in xenograft models, camptothecin inhibited Nrf2 expression and sensitized the cells to various
chemotherapeutic drugs [143]. Camptothecin may enhance the efficacy of combinatorial therapy in
cancers with elevated expression of Nrf2. All these phytochemicals and other molecules may modulate
Nrf2 activation by targeting different molecules in HCC (Table 1).
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Table 1. Phytochemicals and molecules that target different molecules and modulate the Nrf2 pathway in HCC.
Compounds Dose and Duration Cell Lines/Animal Model Molecular Targets Molecular Mechanism Reference
Camptothecin 0.1 and 0.5 µM for 24 h HepG2 ↓GCLC, ↓GCLM, ↓NQO1, ↓HMOX-1,↓AKR1C1, ↓AKR1C2, ↓AKR1C3
Down regulation of NRF2 suppression of
ARE- dependent genes [143]
Capsaicin 200 µM for 24 h HepG2 ↑HO-1, ↓NQO1, ↑p-AKT,↑p-ERK, ↑NRF2
Down regulation of NQO1 triggers the
production of ROS, leading to
phosphorylation of AKT, ERK and ARE
binding of NRF2
[127]
Glycycoumarin 10 mg and 20 mg/kg foronce a day for 3 weeks C57BL/6 mice ↑NRF2, ↑HO-1, ↑GCLC
Glycycoumarin activates NRF2 and
induces autophagy via up regulation of
p62 and p38
[144]
Glycycoumarin 50 µM for 24 h HepG2 ↑Nrf2, ↑HO-1, ↑GCLC, ↑p38,↑p-ERK1/2, ↑p62, ↓KEAP1, ↑LC3-II Glycycoumarin activates NRF2 [144]
Crotonaldehyde 50 µM for 24 h HepG2 ↑HO-1, ↑p38, ↑p-PKC-δ, ↑NRF2
Anti-apoptotic effect of crotonaldehyde
induced by HO-1 through the PKC-δ-p38
MAPK-NRF2 signalling pathway
[129]
Pelargonidin Chloride 50 and 100 µM for 2 h HepG2 ↑NRF2, ↑HO-1, ↑GST, ↑NQO1, ↑CAT,↑SOD1, ↑GPX1
Up regulation of detoxification enzymes
genes through the KEAP1/NRF2
signalling pathway
[136]
Pomegranate emulsion 1 g and 10 g/kg for threetimes a week Male Sprague-Dawley rats
↑GSTA2, ↑GSTA5, ↑GSTM1,
↑GSTM7, ↑GSTT1, ↑NQO1,
↑UGT1A1, ↑UGT2B17, ↑NRF2
Induction of antioxidant and phase 2
xenobiotic enzymes leading to up
regulation of NRF2
[140]
Ruthenium complex 2 and 4 µM for 24 h HepG2 ↓NRF2, ↓NQO1, ↓HO-1
Suppression of NQO1 and HO-1
expression through down regulation of
the Nrf2 signalling pathway
[145]
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12. Phytochemicals/Molecules Sensitizing Resistant HCC through Nrf2 Signalling
Chemotherapy resistance is a common threat in the treatment of HCC. Phytochemicals
and molecules have the potential to sensitize chemoresistant HCC cells (Figure 6). Apigenin
(4′,5,7-trihydroxyflavone) is a natural bioflavonoid that has exhibited anti-cancer properties against
various cancers. The sensitivity of doxorubicin resistant HCC (BEL-7402/ADM) was enhanced by
apigenin at non-toxic concentrations [146]. The cytotoxicity of BEL-7402/ADM cells was increased
when apigenin increased the intracellular concentration of adriamycin (ADM). The PI3K/Akt pathway
offers chemoresistance to cancers through Nrf2 activation. Apigenin, as an effective adjuvant sensitizer
with ADM, inhibits the PI3K/Akt pathway and its downstream Nrf2 pathway, thus sensitizing the
BEL-7402/ADM cells to ADM. Yet another natural flavonoid, chrysin (5,7-dihydroxyflavone) sensitizes
ADM resistant BEL-7402/ADM cells to doxorubicin through inhibition of the PI3K-Akt and ERK
pathways [147]. The inhibition of these pathways ultimately suppresses Nrf2 expression and reverses
the drug-resistant phenotype in BEL-7402/ADM cells.
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tea [148]. The hepatoprotective effect and anti-tu i it f C were reported in mice [149]
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in BEL-7402/5-FU cells reveal d that DMC inhibited drug efflux by decr asing the intracellular GST
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Cancers 2018, 10, 481 16 of 29
Sorafenib (Nexavar) is a multi-kinase inhibitor, which is used as an anti-cancer agent, particularly
against advanced HCC [152]. Sorafenib interferes with cell growth and invasion. The chemoresistance
to 5-FU is a serious problem in HCC. Sorafenib reduces the 5-FU resistance in BEL-7402/5-FU cells,
wherein the suppression of Nrf2 is the reverse mechanism [153]. Hence, sorafenib could be used as an
Nrf2 inhibitor in HCC.
Ursolic acid (UA) is a lipophilic pentacyclic triterpenoid that imparts a smooth waxy appearance
to fruits, particularly apples and is found in many fruits and herbs [154]. The reversal of resistance
to cisplatin was brought about in cisplatin-resistant HepG2/DDP cells by UA [155]. The inhibition
of Nrf2 signalling is the primary mechanism utilized by UA. Hence, UA can be utilized as a natural
adjuvant sensitizer in cisplatin chemoresistant HCC.
Valproic acid (VPA)—a branched short-chain fatty acid, is the primary food and drug
administration (FDA) approved drug for epilepsy and is a histone deacetylase inhibitor [156,157].
VPA sustained the proton beam generated ROS and DNA damage, eventually leading to apoptosis in
Hep3B cells. VPA was shown to have a synergistic effect on proton beam irradiation [158]. The Nrf2
expression was suppressed not only in the Hep3B cells but also in Hep3B tumour xenograft models.
Thus, VPA acts as a radiosensitizer in HCC targeting the Nrf2 signalling pathway. Investigations
revealed that phytochemicals and other molecules have the potential to sensitize chemoresistant HCC
through the suppression of Nrf2 (Table 2).
13. Endoplasmic Reticulum Stress and Nrf2 Signalling in HCC
The endoplasmic reticulum (ER) is the primary organelle that regulates multiple functions such
as Ca2+ homeostasis, protein folding and trafficking, post-translational modification of proteins and
lipid synthesis [159]. The microenvironment of normal tissues is different to that of the tumour
microenvironment; the latter has hypoxia, low pH, lack of nutrients, physical pressure, immune
surveillance and an imbalance between oxidants and antioxidants [160]. These factors perturb ER
functions and can lead to ER stress in tumour cells [161]. In order to expand the tumours, ER stress can
mediate to re-establish homeostasis and provides- ideal conditions for progression and survival [162].
When the ER stress response fails to restore homeostasis, apoptosis may be triggered. In HCC (HepG2,
MHCC97L and xenograft), the elevated expression of fibroblast growth factor 19 (FGF19) and fibroblast
growth factor receptor 4 (FGFR4) directs them to induce a cell survival response [163]. ATF4 -an ER
stress inducible transcription factor- regulates the expression of FGF19 by binding to the promoter of
FGF19. Further investigation from FGFR4 knockout studies revealed that FGFR4 is involved in the
resistance to ER stress. The FGF19-FGFR4 axis ultimately induced Nrf2 accumulation through GSK3β.
The phosphorylation at specific residues of GSK3β led to the inhibition of GSK3β and facilitated Nrf2
nuclear accumulation, which eventually offered cytoprotection. Thus, targeting the FGF19-FGFR4 axis
might also aid in the treatment of HCC.
14. Metal Complexes and Nrf2 in HCC
Some metal complexes have displayed anti-cancer activities [164], among which ruthenium
(Ru)-based complexes inhibited the proliferation, migration and invasion of HCC [145]. Of the
two Ru complexes tested; 2,3,7,8,12,13,17,18-Octaethyl-21H,23H-porphine u(II) carbonyl (Ru1) and
5,10,15,20-Tetraphenyl-21H,23H-porphine Ru(II) carbonyl (Ru2), Ru2 exhibited potent anti-cancer
activity in both in vitro and in vivo studies. The cytotoxicity of Ru2 against HepG2 cells was much
higher than in L02 human normal liver cells. Besides cell growth, Ru2 inhibited migration and invasion
of HepG2 cells. Ru2 triggered apoptosis through the generation of ROS. Ru2 not only decreased
the expression of Nrf2 but also the downstream targets Nqo1 and HO1. However, research on the
anti-cancer activities of other metal-based complexes against HCC is still in its infancy.
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Table 2. Phytochemicals and molecules that sensitize resistant HCC against chemoresistance drugs.
Compounds Drug Sensitized Dose and Duration Cell Lines Mode of Nrf2 Inhibition Molecular Targets Reference
Apigenin Doxorubicin Apigenin-20 µM for 24 hDoxorubicin-2 µM for 24 h BEL-7402/ADM
NRF2 expression was inhibited by down
regulation of the PI3K/AKT pathway
↓NRF2, ↓HO-1,
↓AKR1B10, ↓MRP5 [147]
Chrysin Doxorubicin Chrysin-20 µM for 24 h BEL-7402/ADM
Chrysin suppressed the activation of
NRF2 and its downstream genes
through inhibition of the PI3K/AKT and
ERK signalling pathway
↓NRF2, ↓HO-1,
↓AKR1B10, ↓MRP5,
↓p-Akt, ↓p-ERK1/2
[148]
DMC 5-FU DMD-5,10 and 20 µM for 24 h BEL-7402/5-FU
NRF2 suppression, prevented NRF2
translocation and inhibited the
ARE binding
↓NRF2, ↓GCLC,
↓GCLM, ↓GST, ↓GSH [151]
Sorafenib 5-FU
Sorafenib-2 µM for 24 h
5-flurouracil-1000 µg/mL for
24 h
Bel-7402/5-FU Sorafenib inhibited the expression ofNRF2 induced by 5-flurouracil
↓NRF2, ↓MRP1,
↓MRP2, ↓MRP3 [153]
Ursolic acid Cisplatin Ursolic acid-2.25 µg/mL for48 h HepG2/DDP
Ursolic acid highly induced ROS and
reduced mitochondrial membrane
potential, leading to suppression of
NRF2 expression and its
downstream genes
↓NRF2, ↓HO-1,
↓NQO1, ↓GST [155]
Valproic acid Proton therapy Valproic acid-1 mM for 2 hand 24 h Hep3B
NRF2 expression was suppressed by
NADPH oxidase activation through
increased intracellular ROS level
↑PARP cleavage,
↑caspase-3 cleavage,
↓NRF2, ↓HO-1
[158]
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15. miRs Regulation/Dysregulation of Nrf2 in HCC
MiR was first identified to play a role in the regulation of development of organisms. In recent
years, a multitude of roles of miRs in cancer have been explored [165]. These are short 18–25 nucleotide
noncoding RNA molecules that regulate the expression of genes post-transcriptionally by binding
with target mRNAs [166]. Research in the past decade unfolded the regulation of Nrf2 by miRs in
HCC and may offer new approaches in the diagnostics and therapeutics for HCC (Figure 7).
Another natural compound, apigenin can chemosensitize the doxorubicin-resistant HCC cell line
BEL-7402/ADM by triggering the expression of miR-101 [167]. miR-101 targets the 3′-UTR of Nrf2 and
negatively regulates Nrf2, thus intensifying the sensitivity of BEL-7402/ADM to doxorubicin. miR-144
regulates chemosensitivity of HCC to 5-FU. 5-FU downregulates the expression of miR-144 and
activates the Nrf2 defensive system, thereby conferring chemoresistance to BEL-7402/5-FU cells [168].
miR-144 directly interacts with the 3′-UTR of Nrf2 mRNA and inhibits the Nrf2/HO-1 pathway, which
plays a vital role in the survival of BEL-7402/5-FU cells. The ectopic miR-144 expression inhibited Nrf2
and augmented the chemosensitivity of HCC cell lines to 5-FU. Yet another miR, miR-340, exhibited a
similar mechanism of action in the HCC HepG2/CDDP cell line and its enhanced expression offered
sensitivity against cisplatin [169]. The decreased expression of miR-340 with a concomitant increased
expression of Nrf2 was detected in HepG2/CDDP cells. The luciferase reporter system revealed that
miR-340 directly targets the 3′-UTR of Nrf2 mRNA in HepG2 cells. This inhibition of Nrf2 by miR-340
offered CDDP resistance to HepG2 cells. The HepG2/CDDP cells exhibited sensitivity to CDDP when
these cells were transfected with miR-340 mimics, which targeted and inhibited Nrf2.
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In contrast to the functions of the above discussed miRs, miR-200a promotes HCC cell growth
through targeting Keap1 in the Nrf2 pathway. miR-200a negatively regulates Keap1 in both
human (HepG2) and rat (FaO and RH) HCC cells when transfected with miR-200a mimics [170].
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When miR-200a negatively regulates Keap1, Nrf2 may elevate the expression of its own target genes,
thereby contributing to increased cell proliferation.
miR-141 expression bestows HCC resistance against 5-FU. 5-FU induces apoptosis in cancer cells
through the depletion of antioxidants and hence is used as a chemotherapeutic agent against various
cancers [171]. The resistance is brought by an increased expression of miR-141. The miR-141 expression
was found to be elevated in HepG2/5-FU, SMMC-7721/5-FU and HuH7/5-Fu cells compared to their
parental counterparts [172]. miR-141 inhibited 5-FU-induced apoptosis in HCC. miR-141 directly
targets the 3′-UTR of Keap1 mRNA and thereby decreases the levels of Keap1 mRNA and protein.
The suppression of Keap1 expression by miR-141 activates the Nrf2 pathway, eventually conferring
resistance of HCC against 5-FU.
Nrf2 can also regulate glucose metabolism, which is essential for tumour growth [173].
The regulation of metabolic genes involves miR-1 and miR-206, which revealed the link between
Nrf2 and these miRs [174]. In both tumour and non-tumour cells, the activation of Nrf2 suppressed
the expression of miR-1 and miR-206 through a redox dependent mechanism. In addition, epigenetic
mechanisms such as DNA methylation and acetylation in the promoter regions of miR-1 and miR-206
can regulate their expression. miR-1 and miR-206 expressions are repressed by hypoacetylation and
cytosine methylation in their promoters. Histone deacetylase 4 (HDAC4) controls the acetylation of
miR-1 and miR-206 promoters. miR-1 and miR-206 targets this HDAC, which in turn controls the
expression of these miRs and thus establishes a regulatory feedback loop. The cysteine residues in the
HDAC4 can be oxidized due to the increased ROS, eventually translocating HDAC4 into the nucleus.
In tumours, persistent Nrf2 activation controls this event and thus inhibits HDAC4 activation, which
thereby attenuates the expression of both miR-1 and miR-206. This attenuation of miR-1 and miR-206
targets the pentose phosphate pathway genes glucose-6-phosphate dehydrogenase, 6-phosphogluconate
dehydrogenase, glycerol-3-phosphate dehydrogenase and transketolase, consequently regulating glucose
metabolism. Moreover, Nrf2 activity can also regulate miR-1 and miR-206 expression and thus controls
glucose metabolism, ultimately leading to the progression of tumour growth. In both human liver
cancers and hepatoma cell lines (HepG2 and Hep3B), miR-1 expression was reduced and its elevated
expression attenuated the proliferation of hepatoma cells [175].
The above studies on miRs revealed that increased or decreased expression of miRs might serve
as a therapeutic strategy to overcome liver cancer, particularly drug resistant HCC. Furthermore,
miRs may serve as potential molecular markers for the diagnosis of Nrf2-stabilized cancers.
16. Conclusions and Future Perspectives
Nrf2 is the primary player in HCC, as evidenced from the many studies demonstrating an
increased expression of Nrf2 associated with HCC. This dysregulated Nrf2 signalling promotes cellular
proliferation, triggers vascularization, invasiveness and confers resistance against drugs. Hence,
this master regulator could serve as a promising therapeutic target in HCC. Naturally occurring
phytochemicals can modulate Nrf2 expression to cause anti-cancer effects in HCC. In addition,
phytochemicals were found to reverse the chemotherapeutic resistance of HCCs and sensitized them
to anti-cancer drugs. Some dietary phytochemicals are also able to modulate Nrf2 expression via miRs
and targeting these miRs will open avenues for therapeutics against HCC. Cancer pharmacologists
around the world are actively involved in the identification of safe and potent Nrf2 inhibitors as
potential drugs against HCC. A comprehensive strategy must be framed in the development of
drugs that target Nrf2 in the prevention and treatment of HCC. Molecular profiling will help in the
identification of novel targets against Nrf2 in HCC. Research on epigenetic regulatory mechanisms of
Keap1 and Nrf2 in HCC is still in its infancy and investigations are warranted in this area. Nrf2 can
control the metabolic reprogramming that favours cellular proliferation in HCC and an approach that
targets this metabolic reprogramming will shed light on the unknown targets for developing treatment
options. Future investigations on the mechanisms that contribute to the Keap1-independent activation
of Nrf2 will also unravel new therapeutic targets against HCC. Numerous hurdles and challenges still
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await scientists to unravel the complexities in the cross talk between Nrf2 and other network signalling
pathways, which may pave the way to identify safe and potent Nrf2 modulators.
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